Abstract
Topiramate is known to be efficacious in migraine prophylaxis, but its optimal dose has not been systematically studied in the Asian population. Here, we show that a fixed low dose of topiramate 25 mg/day is efficacious in migraine prophylaxis and also attest to advantages in terms of medication cost savings and more favourable side effect profile.
Keywords: Migraine, Prophylaxis, Topiramate, Asian, Dose, Trial
Full Text
The Full Text of this article is available as a PDF (183.1 KB).
Acknowledgments
This study was supported by a grant from Johnson & Johnson Pharmaceuticals.
Conflict of interest
None.
References
- 1.Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology. 2000;55:624–629. doi: 10.1212/wnl.55.5.624. [DOI] [PubMed] [Google Scholar]
- 2.Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23:820–824. doi: 10.1046/j.1468-2982.2003.00592.x. [DOI] [PubMed] [Google Scholar]
- 3.Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490–495. doi: 10.1001/archneur.61.4.490. [DOI] [PubMed] [Google Scholar]
- 4.Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D, MIGR-002 Study Group Topiramate for migraine prevention: a randomised controlled trial. JAMA. 2004;291:565–573. doi: 10.1001/jama.291.8.965. [DOI] [PubMed] [Google Scholar]
- 5.Lee ST, Chu K, Park JE, Park HJ, Park JH, Lee SH, Kim M. Paresthesia as a favourable predictor of migraine prophylaxis using topiramate. Eur J Neurol. 2007;14:654–658. doi: 10.1111/j.1468-1331.2007.01804.x. [DOI] [PubMed] [Google Scholar]
- 6.Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study) Headache. 2007;47:402–412. doi: 10.1111/j.1526-4610.2006.00599.x. [DOI] [PubMed] [Google Scholar]
- 7.Li HL, Kwan P, Leung H, Yu E, Tsoi TH, Hui AC, Sheng B, Lau KK. Topiramate for migraine prophylaxis among Chinese population. Headache. 2007;47:616–619. doi: 10.1111/j.1526-4610.2007.00763_3.x. [DOI] [PubMed] [Google Scholar]
- 8.Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propanolol in migraine prophylaxis. Acta Neurol Scand. 2008;118:301–305. doi: 10.1111/j.1600-0404.2008.01087.x. [DOI] [PubMed] [Google Scholar]
- 9.Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46:642–648. doi: 10.1111/j.1526-4610.2006.00413.x. [DOI] [PubMed] [Google Scholar]
- 10.Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia. 1998;8:1–96. [PubMed] [Google Scholar]
- 11.Silberstein SD. Topiramate in migraine prevention. Headache. 2005;45:S57–S65. doi: 10.1111/j.1526-4610.2005.4501005.x. [DOI] [PubMed] [Google Scholar]
- 12.Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41:968–975. doi: 10.1046/j.1526-4610.2001.01190.x. [DOI] [PubMed] [Google Scholar]
- 13.Korean Topiramate Study Group Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia. 1999;40:1767–1774. doi: 10.1111/j.1528-1157.1999.tb01596.x. [DOI] [PubMed] [Google Scholar]
- 14.Lim SH, Kwan HC, Sjahrir MJ. An open label trial of topiramate as adjunctive therapy in Asian patients with refractory partial epilepsy. Neuro J Southeast Asia. 2001;6:121–127. [Google Scholar]